These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33815487)

  • 21. Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis.
    Chun HJ; Kim ER; Lee M; Choi DH; Kim SH; Shin E; Kim JH; Cho JW; Han DH; Cha BS; Lee YH
    Metabolism; 2023 Aug; 145():155612. PubMed ID: 37277060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis.
    Sayour AA; Celeng C; Oláh A; Ruppert M; Merkely B; Radovits T
    Diabetologia; 2021 Apr; 64(4):737-748. PubMed ID: 33483761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
    Andreea MM; Surabhi S; Razvan-Ionut P; Lucia C; Camelia N; Emil T; Tiberiu NI
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke.
    Al Hamed FA; Elewa H
    Clin Ther; 2020 Nov; 42(11):e242-e249. PubMed ID: 33008610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.
    Horii T; Oikawa Y; Atsuda K; Shimada A
    J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis.
    Hendryx M; Dong Y; Ndeke JM; Luo J
    PLoS One; 2022; 17(9):e0274519. PubMed ID: 36094949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretreatment body mass index affects achievement of target blood pressure with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease.
    Tsukamoto S; Kobayashi K; Toyoda M; Hatori N; Kanaoka T; Wakui H; Sakai H; Furuki T; Chin K; Ito S; Suzuki D; Umezono T; Aoyama T; Nakajima S; Hishiki T; Hatori Y; Hayashi M; Shimura H; Minagawa F; Mokubo A; Takihata M; Sato K; Miyakawa M; Terauchi Y; Tamura K; Kanamori A
    Hypertens Res; 2024 Mar; 47(3):628-638. PubMed ID: 37848562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
    Diaz-Ramos A; Eilbert W; Marquez D
    Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin.
    Choi MK; Nam SJ; Ji HY; Park MJ; Choi JS; Song IS
    Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32183468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.
    Kashiwagi A; Maegawa H
    J Diabetes Investig; 2017 Jul; 8(4):416-427. PubMed ID: 28178390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of preoperative sodium-glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: A retrospective cohort study.
    Iwasaki Y; Sasabuchi Y; Horikita S; Furukawa T; Shiotsuka J; Lefor AK; Sanui M
    BMC Endocr Disord; 2022 Aug; 22(1):209. PubMed ID: 35987618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium-glucose Cotransporter 2 Inhibitors' Rise to the Backbone of Heart Failure Management: A Clinical Review.
    Rohant N; Kennedy JL
    Heart Int; 2021; 15(1):42-48. PubMed ID: 36277321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats.
    Takeda K; Ono H; Ishikawa K; Ohno T; Kumagai J; Ochiai H; Matumoto A; Yokoh H; Maezawa Y; Yokote K
    BMJ Open Diabetes Res Care; 2021 Apr; 9(1):. PubMed ID: 33879516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor.
    Feng X; Gu Q; Gao G; Yuan L; Li Q; Zhang Y
    Ann Endocrinol (Paris); 2020 Oct; 81(5):476-481. PubMed ID: 32822653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
    Kawasoe S; Maruguchi Y; Kajiya S; Uenomachi H; Miyata M; Kawasoe M; Kubozono T; Ohishi M
    BMC Pharmacol Toxicol; 2017 Apr; 18(1):23. PubMed ID: 28391776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents.
    Choi CI
    Molecules; 2016 Aug; 21(9):. PubMed ID: 27618891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.